文献速递急性肾损伤慢性肾脏病肾小球疾病

肾脏血管内大B细胞淋巴瘤的特征

Characteristics of Renal Intravascular Large B-cell Lymphoma.
PubMed 文献 · Kidney Int Rep · 2022-12-13

该多机构回顾性研究分析了20例经肾活检诊断的肾脏血管内大B细胞淋巴瘤(IVLBCL)患者,平均年龄65.7±7.8岁,55%为男性。最常见临床表现为发热和贫血,急性肾损伤见于70%至90%的病例,蛋白尿见于70%至84.1%的病例。中位生存期为21个月,肾外受累是死亡的显著独立预测因素(HR 4.975,95%CI 1.38-17.88)。

要点

  • 肾脏IVLBCL常以发热、贫血、轻度急性肾损伤和蛋白尿起病。
  • 肾外受累是死亡的显著独立预测因素(HR 4.975,95%CI 1.38-17.88)。
  • 中位生存期为21个月。

核心结论

  • 肾脏IVLBCL是一种罕见疾病,常由肾活检意外诊断,表现为发热、贫血、轻度急性肾损伤和蛋白尿,中位生存期21个月,肾外受累与更差结局相关。

研究设计与样本

  • 多机构回顾性研究,回顾肾脏活检和尸检诊断为肾脏IVLBCL的病例,共纳入20例患者。

主要发现

  • 患者平均年龄65.7±7.8岁,55%为男性。
  • 最常见临床表现为发热和贫血,急性肾损伤见于70%至90%的病例,蛋白尿见于70%至84.1%的病例,血尿见于45%的病例,肾病范围蛋白尿见于10%至26.1%的病例。
  • 血清肌酐中位数(四分位距)为1.75(1.14, 3.3)mg/dl。
  • 肿瘤性淋巴细胞见于肾小球、管周毛细血管和动脉或静脉;44.3%的患者有肾外浸润(骨髓、肝、脾、中枢神经系统、肺和皮肤)。
  • 肿瘤细胞表达CD20、CD79a、PAX-5和MUM1+,CD10阴性;可获得随访数据显示诊断后中位生存期为21个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Renal intravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive B-cell lymphoma with neoplastic cells occupying the vascular lumina with only 53 patients reported to date. Here, we present the largest case series to characterize this rare disease. METHODS: We performed a multi-institutional, retrospective review of kidney biopsies and autopsies with a diagnosis of kidney IVLBCL and report our findings. RESULTS: We identified 20 patients with an average age of 65.7 ± 7.8 years (55% males) with IVLBCL on kidney biopsy. The most common clinical presentation was fever and anemia. Acute kidney injury (AKI) was noted in 70% to 90%, proteinuria in 70% to 84.1%, hematuria in 45%, and nephrotic-range proteinuria in 10% to 26.1% of cases. The median (interquartile range) of serum creatinine was 1.75 (1.14, 3.3) mg/dl. Neoplastic lymphoid cells were present in glomeruli, peritubular capillaries, and arteries or veins. Of the patients, 44.3% showed extrarenal infiltration into bone marrow, liver, spleen, central vervous system, lung and skin. Neoplastic cells express CD20, CD79a, PAX-5, and MUM1+, and were CD10-negative. Available follow-up data showed a median survival of 21 months after diagnosis. Extrarenal involvement is a significant and independent predictor of mortality with a hazard ratio of 4.975 (95% confidence interval:1.38, 17.88) after controlling for age and gender. Serum creatinine, age, sex, and infiltration of intrarenal arteries or veins did not affect survival. CONCLUSION: Kidney IVLBCL is a rare disease that is unexpectedly diagnosed by kidney biopsy, presenting with fever, anemia, mild AKI, and proteinuria. Median survival is 21 months and extrarenal involvement is associated with worse outcome.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Rastogi P, Alrwashdeh A, Caza T, et al. Characteristics of Renal Intravascular Large B-cell Lymphoma. Kidney Int Rep. 2022. PMID: 36938088. doi:10.1016/j.ekir.2022.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。